{"id":5595,"date":"2011-07-01T09:32:00","date_gmt":"2011-07-01T09:32:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=5595"},"modified":"2021-07-09T11:25:33","modified_gmt":"2021-07-09T11:25:33","slug":"adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention\/","title":{"rendered":"Adacolumn therapeutic leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and nonresponders to this nonpharmacologic intervention."},"content":{"rendered":"
\n

H. Hanai, Y. Takeda, M. Eberhardson, R. Gruber, A. R. Saniabadi, O. Winqvist and R. Lofberg, doi:10.1111\/j.1365-2249.2010.04279.x<\/p>\n<\/div>\n\n

\n

imflammatory cytokines include activated myeloid leucocytes, which in patients with IBD are elevated with activation behaviour,selective depletion of these proinflammatory leucocytes by GMA appears to be an attractive strategy to alleviate inflamamation or enhance the efficacy of pharmacological therapy. However, clinical studies have hitherto reported both impressive as well as disappointing efficacy outcomes, indi\u0002cating that patients\u2019 demographic factors might determine
responders or non-responders to GMA. Further, as this non drug-based treatment intervention has an excellent safety
profile, it is very much favoured by patients and our impres\u0002sion is that the use of therapeutic GMA will expand rather than diminish. The MoA of GMA appears to be more than physical depletion of excess and activated GM per se; the release of IL-1ra, HGF, sTNF RI, RII and the rise of regula\u0002tory CD4+ CD25+ T cells are typical effects which are poten\u0002tially very interesting in the context of treating conditions that reflect a dysregulated immune profile<\/p>\n<\/div>\n\n

\n

https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3010911\/pdf\/cei0163-0050.pdf<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

H. Hanai, Y. Takeda, M. Eberhardson, R. Gruber, A. R. Saniabadi, O. Winqvist and R. Lofberg, doi:10.1111\/j.1365-2249.2010.04279.x imflammatory cytokines include activated myeloid leucocytes, which in patients with IBD are elevated with activation behaviour,selective depletion of these proinflammatory leucocytes by GMA appears to be an attractive strategy to alleviate inflamamation or enhance the efficacy of pharmacological […]<\/p>\n","protected":false},"template":"","scientific_tags":[306],"class_list":["post-5595","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-ulcerative-colitis"],"acf":{"sc_authors":""},"yoast_head":"\nAdacolumn therapeutic leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and nonresponders to this nonpharmacologic intervention. - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adacolumn therapeutic leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and nonresponders to this nonpharmacologic intervention. - Adacyte\" \/>\n<meta property=\"og:description\" content=\"H. Hanai, Y. Takeda, M. Eberhardson, R. Gruber, A. R. Saniabadi, O. Winqvist and R. Lofberg, doi:10.1111\/j.1365-2249.2010.04279.x imflammatory cytokines include activated myeloid leucocytes, which in patients with IBD are elevated with activation behaviour,selective depletion of these proinflammatory leucocytes by GMA appears to be an attractive strategy to alleviate inflamamation or enhance the efficacy of pharmacological […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-09T11:25:33+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention\/\",\"name\":\"Adacolumn therapeutic leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and nonresponders to this nonpharmacologic intervention. - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2011-07-01T09:32:00+00:00\",\"dateModified\":\"2021-07-09T11:25:33+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adacolumn therapeutic leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and nonresponders to this nonpharmacologic intervention. - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention\/","og_locale":"fr_FR","og_type":"article","og_title":"Adacolumn therapeutic leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and nonresponders to this nonpharmacologic intervention. - Adacyte","og_description":"H. Hanai, Y. Takeda, M. Eberhardson, R. Gruber, A. R. Saniabadi, O. Winqvist and R. Lofberg, doi:10.1111\/j.1365-2249.2010.04279.x imflammatory cytokines include activated myeloid leucocytes, which in patients with IBD are elevated with activation behaviour,selective depletion of these proinflammatory leucocytes by GMA appears to be an attractive strategy to alleviate inflamamation or enhance the efficacy of pharmacological […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention\/","og_site_name":"Adacyte","article_modified_time":"2021-07-09T11:25:33+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention\/","name":"Adacolumn therapeutic leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and nonresponders to this nonpharmacologic intervention. - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2011-07-01T09:32:00+00:00","dateModified":"2021-07-09T11:25:33+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/adacolumn-therapeutic-leucocytapheresis-for-ulcerative-colitis-clinical-and-endoscopic-features-of-responders-and-nonresponders-to-this-nonpharmacologic-intervention\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/5595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=5595"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=5595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}